Format

Send to

Choose Destination
See comment in PubMed Commons below
World J Gastroenterol. 2014 Aug 14;20(30):10338-47. doi: 10.3748/wjg.v20.i30.10338.

Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance.

Author information

  • 1Javier Molina-Infante, Department of Gastroenterology, Hospital San Pedro de Alcantara, 10003 Caceres, Spain.

Abstract

The efficacy of triple therapy for Helicobacter pylori infection has dramatically declined over the last decade, largely related to increasing clarithromycin resistance rates. From a microbiological standpoint, bismuth quadruple therapy is the ideal replacement since it combines drugs for which resistance does not impair its efficacy. Nonetheless, several obstacles such as availability, complexity or tolerance prevent a general implementation of bismuth quadruple therapy, so non-bismuth quadruple regimens remain the best first-line treatment in clinical practice in many geographical areas. We review the rationale and efficacy of several optimization tools (increasing the length of duration, high-dose acid suppression, probiotics), which have been largely evaluated over the last 5 years to increase the effectiveness of standard triple therapy. Then, we update available evidence on the effectiveness of several non-bismuth quadruple therapies (sequential, concomitant, hybrid, miscellaneous therapy), which have gained interest lately. We also revise evidence on the efficacy of the aforementioned optimization tools for non-bismuth quadruples schemes and, finally we provide a novel regionalized therapeutic algorithm, based on novel formulas recently developed for predicting the outcome of non-bismuth quadruple regimens, upon local antibiotic resistance rates.

KEYWORDS:

Antibiotic resistance; Bismuth; Clarithromycin; Concomitant; Eradication; Helicobacter pylori; Hybrid; Sequential

PMID:
25132750
PMCID:
PMC4130841
DOI:
10.3748/wjg.v20.i30.10338
[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
    Loading ...
    Support Center